Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target Raised to $31.00 at HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP) had its price objective upped by HC Wainwright to $31.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Wall Street Zen upgraded Acurx Pharmaceuticals to a “sell” rating in a research note on Saturday.

Acurx Pharmaceuticals Stock Performance

ACXP stock opened at $4.43 on Tuesday. Acurx Pharmaceuticals has a 1 year low of $3.80 and a 1 year high of $47.80. The firm has a market cap of $6.82 million, a P/E ratio of -0.41 and a beta of -1.27. The stock has a 50-day simple moving average of $8.53 and a 200-day simple moving average of $9.46.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its earnings results on Monday, August 11th. The company reported ($1.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.11. On average, equities research analysts predict that Acurx Pharmaceuticals will post -0.89 EPS for the current year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ACXP. Vanguard Capital Wealth Advisors acquired a new stake in Acurx Pharmaceuticals during the 1st quarter valued at approximately $26,000. O Brien Greene & Co. Inc acquired a new stake in Acurx Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Finally, Prospect Financial Services LLC grew its stake in Acurx Pharmaceuticals by 11.4% during the 1st quarter. Prospect Financial Services LLC now owns 366,576 shares of the company’s stock valued at $143,000 after purchasing an additional 37,500 shares in the last quarter. Institutional investors and hedge funds own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.